MedTrace Logo

A Study of Mycophenolate Mofetil Combined With Glucocorticoid Therapy in Relapse Vogt-Koyanagi-Harada Disease

NCT05627739 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 15

Last updated 2023-12-07

No results posted yet for this study

Summary

This project is designed to test the hypothesis that Mycophenolate Mofetil is clinically useful for patients with relapse Vogt-Koyanagi-Harada disease

Conditions

  • Vogt-Koyanagi-Harada Disease
  • Mycophenolate Mofetil

Interventions

DRUG

Mycophenolate Mofetil

Glucocorticoid is started at a dose of 0.5-0.8 mg/kg/day, and 60 mg daily was the highest dose. Mycophenolate mofetilwas is started at a dose of 0.5-1.0g bid.

Sponsors & Collaborators

  • Tianjin Medical University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-01
Primary Completion
2024-12-01
Completion
2025-12-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05627739 on ClinicalTrials.gov